The pathological appearance of renal tumours

2007 ◽  
pp. 47-59
Author(s):  
Stewart Fleming
Keyword(s):  
Renal Tumours ◽  
Pathological Appearance

1029: Skipping is Still a Common Problem with Radiofrequency Ablation of Small Renal Tumours

2006 ◽  
Vol 175 (4S) ◽  
pp. 331-332 ◽  
Author(s):  
Hans-Christoph Klingler ◽  
Julian Mauermann ◽  
Mesut Remzi ◽  
Joachim Kettenbach ◽  
Martin Susani ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Renal Tumours

1400: Early Clinical Experience Using High-Intensity Focused Ultrasound for the Treatment of Renal Tumours

2005 ◽  
Vol 173 (4S) ◽  
pp. 379-380
Author(s):  
James E. Kennedy ◽  
Rowland O. Illing ◽  
Feng Wu ◽  
Gail R. ter Haar ◽  
Rachel R. Phillips ◽  
...  
Keyword(s):  
Clinical Experience ◽  
High Intensity ◽  
Focused Ultrasound ◽  
High Intensity Focused Ultrasound ◽  
Early Clinical Experience ◽  
Renal Tumours

Real-time US/cone-beam CT fusion imaging for percutaneous ablation of small renal tumours: a technical note

2021 ◽  
Author(s):  
Lorenzo Monfardini ◽  
Nicolò Gennaro ◽  
Franco Orsi ◽  
Paolo Della Vigna ◽  
Guido Bonomo ◽  
...  
Keyword(s):  
Real Time ◽  
Cone Beam Ct ◽  
Fusion Imaging ◽  
Technical Note ◽  
Cone Beam ◽  
Percutaneous Ablation ◽  
Renal Tumours

scholarly journals Clinical Implications of (Pro)renin Receptor (PRR) Expression in Renal Tumours

Diagnostics ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 272
Author(s):  
Jon Danel Solano-Iturri ◽  
Enrique Echevarría ◽  
Miguel Unda ◽  
Ana Loizaga-Iriarte ◽  
Amparo Pérez-Fernández ◽  
...  
Keyword(s):  
Renal Cell ◽  
Tumour Progression ◽  
Renin Angiotensin System ◽  
Staging System ◽  
Staining Intensity ◽  
Renal Oncocytoma ◽  
Angiotensin System ◽  
Promising Therapeutic Target ◽  
Renal Tumours ◽  
Grade Tumour

(1) Background: Renal cancer is one of the most frequent malignancies in Western countries, with an unpredictable clinical outcome, partly due to its high heterogeneity and the scarcity of reliable biomarkers of tumour progression. (Pro)renin receptor (PRR) is a novel receptor of the renin–angiotensin system (RAS) that has been associated with the development and progression of some solid tumours by RAS-dependent and -independent mechanisms. (2) Methods: In this study, we analysed the immunohistochemical expression of PRR at the centre and border in a series of 83 clear-cell renal cell (CCRCCs), 19 papillary (PRCC) and 7 chromophobe (ChRCC) renal cell carcinomas, and the benign tumour renal oncocytoma (RO, n = 11). (3) Results: PRR is expressed in all the tumour subtypes, with higher mean staining intensity in ChRCCs and ROs. A high expression of PRR at the tumour centre and at the infiltrative front of CCRCC tissues is significantly associated with high grade, tumour diameter, local invasion and stage, and with high mortality risk by UCLA integrated staging system (UISS) scale. (4) Conclusions: These findings indicate that PRR is associated with the development and progression of renal tumours. Its potential as a novel biomarker for RCC diagnosis/prognosis and as a promising therapeutic target should be taken into account in the future.

scholarly journals Birt–Hogg–Dubé syndrome

2020 ◽  
Vol 29 (157) ◽  
pp. 200042
Author(s):  
Cécile Daccord ◽  
Jean-Marc Good ◽  
Marie-Anne Morren ◽  
Olivier Bonny ◽  
Daniel Hohl ◽  
...  
Keyword(s):  
Index Patient ◽  
Suppressor Gene ◽  
Tumour Suppressor Gene ◽  
Autosomal Dominant Disorder ◽  
Cystic Lung ◽  
Pulmonary Langerhans Cell Histiocytosis ◽  
Renal Tumours ◽  
Pulmonary Cysts ◽  
Chronic Respiratory Insufficiency ◽  
Diagnostic Work

Birt–Hogg–Dubé syndrome (BHD) is a rare inherited autosomal dominant disorder caused by germline mutations in the tumour suppressor gene FLCN, encoding the protein folliculin. Its clinical expression typically includes multiple pulmonary cysts, recurrent spontaneous pneumothoraces, cutaneous fibrofolliculomas and renal tumours of various histological types. BHD has no sex predilection and tends to manifest in the third or fourth decade of life. Multiple bilateral pulmonary cysts are found on chest computed tomography in >80% of patients and more than half experience one or more episodes of pneumothorax. A family history of pneumothorax is an important clue, which suggests the diagnosis of BHD. Unlike other cystic lung diseases such as lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis, BHD does not lead to progressive loss of lung function and chronic respiratory insufficiency. Renal tumours affect about 30% of patients during their lifetime, and can be multiple and recurrent. The diagnosis of BHD is based on a combination of genetic, clinical and/or skin histopathological criteria. Management mainly consists of early pleurodesis in the case of pneumothorax, periodic renal imaging for tumour detection, and diagnostic work-up in search of BHD in relatives of the index patient.

RADIOFREQUENCY ABLATION FOR RENAL TUMOURS: INTERMEDIATE TERM RESULTS

2008 ◽  
Vol 7 (3) ◽  
pp. 309 ◽  
Author(s):  
K. Williams ◽  
S. Wingo ◽  
I. Carey ◽  
J. Leveillee
Keyword(s):  
Radiofrequency Ablation ◽  
Renal Tumours

Topographic distribution of sentinel lymph nodes in patients with renal tumours

2017 ◽  
Vol 16 (3) ◽  
pp. e1347
Author(s):  
T. Kuusk ◽  
N. Grivas ◽  
M. Donswijk ◽  
W. Prevoo ◽  
S. Horenblas ◽  
...  
Keyword(s):  
Lymph Nodes ◽  
Sentinel Lymph Nodes ◽  
Renal Tumours ◽  
Topographic Distribution
Sign in / Sign up

Export Citation Format

Share Document